Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
about
A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitisThe synovio-entheseal complex in enthesoarthritis.Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48.Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trialSerum from patients with ankylosing spondylitis can increase PPARD, fra-1, MMP7, OPG and RANKL expression in MG63 cells.Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation.Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro.Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.Developments in the scientific and clinical understanding of the spondyloarthritidesOsteoimmunology in rheumatic diseasesAssessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis.Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.The balance of tissue repair and remodeling in chronic arthritis.MRI and X-ray in axial spondyloarthritis: the relationship between inflammatory and structural changes.Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis.Treatment challenges in axial spondylarthritis and future directions.Mechanism of New Bone Formation in Axial Spondyloarthritis.Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors.Celastrol: A Spectrum of Treatment Opportunities in Chronic DiseasesThe natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features.High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception CMRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis.Synovitis in spondyloarthritides.The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.Evaluation of destruction in a collagen-induced arthritis rat model: Bony spur formation.Inhibition of inflammation but not ankylosis by glucocorticoids in mice: further evidence for the entheseal stress hypothesis.Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis.Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis.Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α.Positron emission tomography/computed tomography: a clinical tool for evaluation of enthesitis in patients with spondyloarthritides.Spondyloarthropathy: frontier for molecular targets?Value of multidetector computed tomography for the radiologic grading of sacroiliitis in ankylosing spondylitis.In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis.Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study.Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.
P2860
Q28943358-2D81D02F-2150-462D-B11C-34DDA2B2D8CCQ33360030-AD4879AF-325D-4F53-8478-A4C60E855EC1Q35012163-358E016C-4390-40DB-91A3-EB220F2D9DD4Q35537104-28B86E05-CBC4-45C1-898E-FC0082934311Q36273419-CE715576-217E-4AE9-8C44-30D60213DCB9Q36304001-E6685CA3-B44C-4D8A-A04E-81BC68EC8CD3Q36346823-E3161BCB-23A9-4B7F-AC1D-80F5C6861314Q36682809-797B542E-DE45-4832-95B2-D7FC49950157Q36993320-D9BAE479-A3AF-49D8-9DFA-425A36E9D90BQ37207018-F956596B-B6C3-49C4-BC64-D81E311FAED0Q37207025-3F248A0B-7CF6-4D5D-9F8F-A5F0B9B98A02Q37350944-65E6627F-19D9-4DA5-8476-26B5C0241986Q37480069-0E9842C5-D9B8-4503-8AC4-60F21E6CAFB3Q37609095-EE9F6108-5FF3-4B05-8508-E7E33D5EAAFCQ37729028-8477EAC0-A05D-4480-873D-4E656F9CC256Q37834956-7A11FB85-243C-44DB-861C-E845B2AC880EQ37873493-72FC1E5B-BC98-492A-BD1F-BCE9CF01219CQ37947117-DD043FAF-B0E3-4847-A04D-33AFE36FC4D8Q38004583-7C33ED1F-5C12-4F1E-9E7F-1B3D6CAEC48BQ38068590-0464CAA4-30FD-400E-B447-61BA7709AF43Q38124281-011CACF9-E133-45BD-B50F-152F80E3D03AQ38655991-2153C804-D018-413E-8F80-9100D244FAB4Q39328132-0A42E9D7-4282-4E1B-A315-9DC16F6B60E5Q39406168-0A2DB978-40B0-4652-8531-4CA359CE3BB6Q39735553-9AC3B220-7004-4359-AA9F-7DF87348FB44Q39812956-FE46CB4B-BEA6-4332-85EB-2122E26268E3Q40436845-881F3C15-39A6-4871-843C-0455B2343B9EQ40577128-6B81CEAE-BB7B-4AD9-847C-243DC0E85C58Q41396084-49A55612-EFB2-48AF-885A-06D006736578Q41672116-2B673EB3-C9B3-4077-8517-7C2AE2045135Q41961746-055E8094-F5B9-4527-823C-FF5D2EA22888Q42362626-7DF0C8AD-409A-4BB0-90B9-BCC79C78FFCDQ42534690-CB72F41E-5EAF-4682-A3D5-A6297D22C437Q42914686-5BBF7DFE-BFAF-4A42-BEFD-62EE1C9BB996Q43223418-0278417E-2A63-4520-86B0-2925C33DADE3Q44066703-38449CFC-0848-457A-8784-DB4B9C04B201Q44824972-ED2BF8D9-D029-469C-A812-B6FF68BF3503Q45102170-94160C3B-91BB-4138-B925-1D730F1DF917Q45250384-8FA4E9A2-3F87-465A-855E-A901025A6C1CQ48008160-6AC1F664-EB6B-4802-B020-FD495B23F30F
P2860
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Critical appraisal of assessme ...... ations for treatment outcomes.
@en
Critical appraisal of assessme ...... ations for treatment outcomes.
@nl
type
label
Critical appraisal of assessme ...... ations for treatment outcomes.
@en
Critical appraisal of assessme ...... ations for treatment outcomes.
@nl
prefLabel
Critical appraisal of assessme ...... ations for treatment outcomes.
@en
Critical appraisal of assessme ...... ations for treatment outcomes.
@nl
P2093
P356
P1476
Critical appraisal of assessme ...... ations for treatment outcomes.
@en
P2093
Heiner Appel
Joachim Sieper
Jürgen Braun
Martin Rudwaleit
P304
P356
10.1002/ART.23260
P577
2008-03-01T00:00:00Z